According to the World Health Organization, neurological diseases account for 6.3 percent of the Asia-Pacific disease burden and are one of the top causes of mortality, accounting for 13.2 percent of deaths in high-income countries and 16.8 percent in low- and middle-income countries. The high mortality and sickness load increase clinical urgency for long-term treatments such as deep brain stimulators. Furthermore, as the public becomes increasingly aware of the enormous burden of neurological disease, there is a greater demand for deep brain stimulators as an alternative therapy. This is projected to propel market expansion throughout the forecast period. Deep brain stimulators are being driven by the increasing occurrence of neurological disorders such as Parkinson's disease, essential tremors, dystonia, and epilepsy.
